Dechra Pharmaceuticals (LSE:DPH) Total Current Assets : £467.9 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Dechra Pharmaceuticals's total current assets for the quarter that ended in Jun. 2023 was £467.9 Mil.

Dechra Pharmaceuticals Total Current Assets Historical Data

The historical data trend for Dechra Pharmaceuticals's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Total Current Assets Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Current Assets

Get a 7-Day Free Trial

291.50

448.90

392.20

444.40

467.90

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Current Assets	Get a 7-Day Free Trial															392.20	376.00	444.40	459.30	467.90

Dechra Pharmaceuticals Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Dechra Pharmaceuticals's Total Current Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	74.4	+	161.9	+	217.3	+	14.3
	=	467.9

Dechra Pharmaceuticals's Total Current Assets for the quarter that ended in Jun. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	74.4	+	161.9	+	217.3	+	14.3
	=	467.9

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Dechra Pharmaceuticals (LSE:DPH) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Dechra Pharmaceuticals's Liquidation Value for the quarter that ended in Jun. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	74.4	-	814.2	+	0.75 * 144.2	+	0.5 * 217.3
=	-523.0

Dechra Pharmaceuticals Total Current Assets Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines